CMS Locks In Permanent Medicare Drug Negotiation Rules, With Up To 20 New Drugs Due By Feb. 1, 2027
The final rule covers prices effective in 2029 and sets up the program's fourth negotiation cycle.
The Centers for Medicare & Medicaid Services (CMS) finalized a permanent framework for negotiating prices of high-cost drugs in Medicare, covering prices that take effect in 2029. The agency must pick up to 20 more drugs for the fourth negotiation cycle by Feb. 1, 2027.
The next round of drug picks
CMS said the rule sets policy for the Medicare Drug Price Negotiation Program starting with 2029 prices, which the agency said gives manufacturers more predictability.
By Feb. 1, 2027, CMS will select up to 20 additional negotiation-eligible drugs covered under Part D (Medicare's prescription drug benefit) and/or payable under Part B (which covers drugs given in clinics and hospitals). It will also choose drugs for renegotiation, as appropriate, for the fourth cycle.
CMS Administrator Dr. Mehmet Oz said President Trump "directed us to lower drug costs for Americans using every tool at our disposal." He said the rule gives CMS more tools to negotiate better deals and deliver greater savings for taxpayers and beneficiaries.
Combination drugs, small biotechs and Part D plans
The rule finalizes a proposed policy on specific fixed combination drugs that CMS determines are new formulations of existing drugs. CMS said it believes the policy removes an incentive for the primary manufacturer to move patients to the new formulation and sidestep the maximum fair price (MFP), the negotiated price.
The rule also implements the Temporary Floor for Small Biotech Drugs, as required by law. For certain eligible small biotech drugs, CMS may not offer or accept a counteroffer for an MFP below a set floor in initial price applicability years 2029 and 2030.
Two Part D policies are codified as well, consistent with statute. Plans must include selected drugs with an MFP in effect on their formularies, and the negotiated prices plans pay dispensing entities are limited to the MFP plus any dispensing fees.
The next dated step is Feb. 1, 2027, when CMS is to name the drugs for the fourth cycle.
Sources
- CMS Final Rule Strengthens Supports Lasting Drug Savings — Centers for Medicare & Medicaid Services
- Will Democrats Pass Medicare for All? 5 Ideas Proposed for New Congress - Newsweek — newsweek.com
- Medicare will cut billions from 340B, expand site-neutral payments in 2027 | Healthcare Dive — healthcaredive.com
- Democrats' big challenge on health care costs — Axios
- Medicare Patients Could Save $900 Under New 2027 Rules - Newsweek — newsweek.com
- The 2026 election wins could allow Democrats to tackle healthcare costs. What can they do? | Vox — vox.com